Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Gastric Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
6 drugs · 167 active trials
4 drugs · 97 active trials
Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| PD1 Inhibitor | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | May 1, 2025 |
| Sapanisertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Taselisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Temozolomide | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 6, 2015 |
| Trametinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Trastuzumab Deruxtecan Regimen | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jan 31, 2022 |
| Zongertinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 28, 2024 |
| Cabazitaxel | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2011-06 |
| Filgrastim | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 1997-12 |
| Lapatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2004-12 |
| Niraparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | Aug 29, 2017 |
| Avelumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Jan 24, 2019 |
| Bortezomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2003-04 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2002-06 |
| Sorafenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2005-10 |
| Aflibercept | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2013-01 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2011-01 |
| Catumaxomab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-07 |
| Cemiplimab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Feb 11, 2022 |
| Hydroxyurea | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 1997-12 |
| Imatinib Mesylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2004-03 |
| Infigratinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | May 13, 2020 |
| Luminespib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2010-04 |
| Pazopanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2011-07 |
| Raltitrexed | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2015-05 |
| Taxol | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2004-04 |
| Vandetanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2008-05 |
| Alpelisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 1, 2020 |
| Alvocidib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-09 |
| AZD-4547 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-09 |
| Celecoxib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-10 |
| Ceritinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2015-12 |
| Dacomitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-07 |
| Derazantinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 6, 2020 |
| Dordaviprone | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 3, 2015 |
| Dovitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-09 |
| Erlotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-12 |
| Gefitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2003-07 |
| Ibrutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 1, 2015 |
| Lurbinectedin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | May 6, 2016 |
| Paclitaxel Liposome | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-12 |
| Panitumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-01 |
| Panobinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-06 |
| Pegfilgrastim | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-04 |
| Pralatrexate | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-09 |
| Romidepsin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-10 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 17, 2012 |
| Sorafenib Tosylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-02 |
| Vinorelbine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2000-06 |
| Vistusertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 1, 2017 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.